Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVX-121 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| IVX-121 | BIOLOGICAL | 75 mcg of IVX-121 without MF59® |
| IVX-241 | BIOLOGICAL | 75 mcg of IVX-241 without MF59® |
| Placebo | BIOLOGICAL | Diluent |
| MF59® | OTHER | MF59® as an adjuvant |
IVX-121 is an investigational monoclonal antibody developed by AstraZeneca PLC. It is in Phase 1 clinical development, and the specific disease or condition it is intended to treat has not been disclosed. It is not an approved medicine and remains under study.
IVX-121 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program studying this monoclonal antibody candidate.
IVX-121 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this candidate.
IVX-121 has been studied in one Phase 1 trial, NCT05664334, titled Safety and Immunogenicity of IVX-A12 in Healthy Older Adults. That trial enrolled 140 participants, was uncontrolled, and is now completed. No active trials of IVX-121 are currently listed.
IVX-121 is associated with the clinical program referenced as IVX-A12 in the completed Phase 1 trial NCT05664334, which evaluated safety and immunogenicity in healthy older adults. The trial enrolled 140 participants and is listed as completed.
Across the IVX-121 clinical program, 140 participants have been enrolled. That enrollment comes from the single completed Phase 1 trial, NCT05664334, which studied safety and immunogenicity in healthy older adults. The trial was uncontrolled and not randomized.